Alacrity Medical Innovations (AMI) seeks to transform the treatment of life-interrupting bleeding, initially for patients on anticoagulant medications (“blood thinners”) and ultimately for a broader population. We are developing novel, convenient devices for anti-coagulated patients to stop life-interrupting bleeding events at home. Alacrity Medical Innovations’ (AMI) first product is a patent-pending, novel, easy-to-use drug delivery device in combination with a unique indication for an anti-fibrinolytic (“blood clot stabilizer”). Our device will simultaneously absorb blood while delivering the anti-fibrinolytic directly to wounds to stop life-interrupting bleeding in anti-coagulated patients.
8 million patients estimated to be on anticoagulants (ACs).
IBM Truven Health Analytics, 12 months ending December 31, 2018 for Commercial, Medicare and Medicaid patients (October 24, 2019).
2.8 million AC treatment visits in Q4 '14 (+38% vs Q2 '09).
Annualizes to >11 million visits in 2015.
Barnes G et al. National Trends in Ambulatory Oral Anticoagulant Use. Am J Med. 2015 December ; 128(12): 1300–1305.e2.
Available by health-care provider prescription
A topical formulation of well established anti-fibrinolytic drug.
Hand-held device to apply direct pressure and administer the medication.
Stops bleeding in a clinical or home setting saving time and the potential need for an Emergency Room or Urgent Care visit.